-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
Latest News
-
September 2026: This month in Huntington’s disease research
5 min read
September brought progress across the HD research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in Huntington’s disease research.
-
A shot in the arm for HTT lowering: INSIGHTT trial begins testing SRP-1005
6 min read
A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an important new arrow to the HD drug development quiver.
-
The 2026 HDBuzz Prize for Young Science Writers Is Open!
4 min read
Announcing the 2026 HDBuzz Prize for Young Science Writers – sponsored by the Huntington’s Disease Foundation!
-
HD2026 Milton Wexler Biennial Symposium Day 3
25 min read
Day 3 of #HD2026 put HTT under the microscope. Researchers shared new insights into HTT1a, next-generation HTT-lowering approaches, somatic expansion, brain circuitry, and why boosting healthy HTT might help. Read our roundup here.
-
HD2026 Milton Wexler Biennial Symposium Day 2
22 min read
Day 2 of #HD2026 brought us updates on the mechanics of somatic instability, new ways to track HD in people, AI tools to help drive research forward, and developments in our understanding of the HTT protein. Catch up right here.
-
HD2026 Milton Wexler Biennial Symposium Day 1
27 min read
Day 1 of HD2026 is a wrap! From what human brains can teach us about HD, to HTT1a, somatic CAG expansion and the normal biology of HTT, today’s talks spanned the spectrum from fundamental biology to potential treatments.
-
Prilenia shares HD trial data with CHDI to help future research
6 min read
Clinical trial data can drive discovery long after a study ends. Prilenia donated placebo-arm data from 2 HD clinical trials to CHDI, a valuable resource for researchers to better understand placebo effects, HD progression and future trial design.
-
Looking back and moving forward: Questions and lessons 4 weeks out from Roche’s disappointing news
10 min read
Roche’s decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn’t end there. Years of research answered some key questions, raised many new ones, and will inform the next generation of HD trials.
-
July 2026: This Month in Huntington’s Disease Research
8 min read
July was a hard month for Huntington’s disease research, with Roche ending two HD programs. But the month also brought promising new tools, a new player in somatic expansion, and important work on eating and self-awareness in HD.
-
Putting it in print: a clinical trial trying to rein in runaway pruning
9 min read
Four years after announcing positive results in their trial of ANX005 (tanruprubart) for HD, Annexon has formally published the results. It’s safe, hits its target, and may have helped some participants – so what’s the holdup?
-
Joining the Starting Lineup: MutLβ’s Role in DNA Repeat Expansions
7 min read
Scientists have known that MutLβ is linked to repeat expansion but not exactly how. A study reveals that the MutLβ protein complex is a main player supporting and interacting with key DNA repair proteins to drive DNA repeat expansions.
HDBuzz Trial Tracker
Show 10 more Show less
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
